An Open Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety of PHX1149T/Dutogliptin in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Dutogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Phenomix Corporation
- 10 Jun 2017 Biomarkers information updated
- 30 Aug 2011 Additional source identified and integrated (Clinical Trials Register- India).
- 10 Aug 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.